DK1751184T3 - FGF-21 fusionsproteiner - Google Patents

FGF-21 fusionsproteiner

Info

Publication number
DK1751184T3
DK1751184T3 DK05742237T DK05742237T DK1751184T3 DK 1751184 T3 DK1751184 T3 DK 1751184T3 DK 05742237 T DK05742237 T DK 05742237T DK 05742237 T DK05742237 T DK 05742237T DK 1751184 T3 DK1751184 T3 DK 1751184T3
Authority
DK
Denmark
Prior art keywords
fgf
fusion proteins
specific
obesity
diabetes
Prior art date
Application number
DK05742237T
Other languages
Danish (da)
English (en)
Inventor
Wolfgang Glaesner
Rohn Lee Junior Millican
Yu Tian
Sheng-Hung Rainbow Tschang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1751184T3 publication Critical patent/DK1751184T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05742237T 2004-05-13 2005-05-02 FGF-21 fusionsproteiner DK1751184T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57090804P 2004-05-13 2004-05-13
PCT/US2005/015111 WO2005113606A2 (en) 2004-05-13 2005-05-02 Fgf-21 fusion proteins

Publications (1)

Publication Number Publication Date
DK1751184T3 true DK1751184T3 (da) 2009-11-23

Family

ID=92541399

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05742237T DK1751184T3 (da) 2004-05-13 2005-05-02 FGF-21 fusionsproteiner

Country Status (12)

Country Link
US (1) US7576190B2 (de)
EP (2) EP2194064A1 (de)
JP (1) JP2008506635A (de)
AT (1) ATE444306T1 (de)
CA (1) CA2565300A1 (de)
DE (1) DE602005016917D1 (de)
DK (1) DK1751184T3 (de)
ES (1) ES2332100T3 (de)
PL (1) PL1751184T3 (de)
PT (1) PT1751184E (de)
SI (1) SI1751184T1 (de)
WO (1) WO2005113606A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1774017B1 (de) 2004-07-26 2013-05-15 Pfenex Inc. Verfahren zur verbesserten proteinexpression durch strain-engineering
DK1789442T3 (da) * 2004-09-02 2009-11-16 Lilly Co Eli Muteiner af fibroblastvækstfaktor 21
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
EP3415529B1 (de) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modifizierte antikörperkonstantregion
MX2010013333A (es) 2008-06-04 2011-04-05 Amgen Inc Mutantes fgf21 y usos de los mismos.
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
KR20110117666A (ko) * 2009-01-23 2011-10-27 노보 노르디스크 에이/에스 알부민 바인더 ａ-ｂ-ｃ-ｄ-ｅ-를 갖는 ｆｇｆ21 유도체 및 그것의 사용
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
CN102656266B (zh) * 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2359843A1 (de) 2010-01-21 2011-08-24 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
MX342017B (es) 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
EP2595647A1 (de) 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal-modifizierte fgf21-verbindungen
WO2012059873A2 (en) 2010-11-05 2012-05-10 Covx Technologies Ireland, Ltd. Anti-diabetic compounds
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
SG10201601621PA (en) 2011-06-28 2016-04-28 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2548570A1 (de) 2011-07-19 2013-01-23 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
AU2012356219B2 (en) 2011-12-22 2016-03-31 Covx Technologies Ireland Limited Anti-diabetic compounds
ES2640268T3 (es) 2012-02-15 2017-11-02 Novo Nordisk A/S Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
LT2814842T (lt) 2012-02-15 2018-11-12 Novo Nordisk A/S Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
CN104364261B (zh) 2012-06-11 2017-04-05 伊莱利利公司 成纤维细胞生长因子21变体
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh) * 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP4043493A1 (de) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
EP3125921B1 (de) 2014-03-11 2020-07-08 Novartis AG Fgf21-varianten in der verwendung zur behandlung von hiv-haart-induzierten partiellen lipodystrophien
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3154585B1 (de) 2014-06-11 2022-02-23 Kathy A. Green Verwendung von vista-agonisten und antagonisten zur unterdrückung oder verbesserung der humoralen immunität
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN106459222A (zh) * 2014-06-24 2017-02-22 诺和诺德股份有限公司 Mic‑1融合蛋白及其用途
KR102641268B1 (ko) 2014-07-17 2024-02-27 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
HRP20191292T1 (hr) 2014-12-23 2019-10-18 Novo Nordisk A/S Derivati fgf21 i njihova upotreba
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP3722314A1 (de) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017075260A1 (en) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW202216201A (zh) 2016-02-12 2022-05-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
JP7184751B2 (ja) 2016-04-15 2022-12-06 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
EP3678686A1 (de) 2017-09-08 2020-07-15 Bristol-Myers Squibb Company Modifizierter fibroblasten-wachstumsfaktor 21 (fgf-21) für die verwendung in verfahren zur behandlung von nichtalkoholischer steatohepatitis (nash)
CN111601613A (zh) 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
KR20200118092A (ko) * 2018-02-06 2020-10-14 밴쿠버 바이오테크 리미티드 GnRH 길항제로서 GHR-106 단일 클론 항체의 용도
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
AU2019248547B2 (en) 2018-04-02 2025-07-17 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
CN111195349B (zh) * 2018-11-16 2023-02-24 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干粉制剂
EP3935075A4 (de) 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. Polypeptidmolekül und anwendung davon
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
KR20220125289A (ko) 2020-01-08 2022-09-14 브리스톨-마이어스 스큅 컴퍼니 Fgf-21 접합체 제제
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
EP4230216A4 (de) * 2020-07-24 2025-02-19 Jiangsu Gensciences Inc. Insulin-fc-fusionsprotein und anwendung davon
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
KR20240034235A (ko) 2021-07-14 2024-03-13 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 대사 장애를 위한 융합 폴리펩타이드
JP2026502133A (ja) 2022-12-22 2026-01-21 ライフアーク ガラニン－２受容体アゴニスト

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US606805A (en) 1898-07-05 Can-opener
US606830A (en) 1898-07-05 Insulator
US528582A (en) 1894-11-06 Can-opener
US635882A (en) 1898-11-02 1899-10-31 Henry Torrance Jr Refrigerating system.
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
JP2003516731A (ja) * 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
WO2001072957A2 (en) * 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
PT1641483E (pt) 2003-06-12 2008-04-29 Lilly Co Eli Proteínas de fusão

Also Published As

Publication number Publication date
ATE444306T1 (de) 2009-10-15
JP2008506635A (ja) 2008-03-06
EP1751184B1 (de) 2009-09-30
WO2005113606A3 (en) 2006-05-04
EP1751184A2 (de) 2007-02-14
PT1751184E (pt) 2009-11-10
US20070237768A1 (en) 2007-10-11
SI1751184T1 (sl) 2010-01-29
WO2005113606A2 (en) 2005-12-01
DE602005016917D1 (de) 2009-11-12
EP2194064A1 (de) 2010-06-09
PL1751184T3 (pl) 2010-02-26
CA2565300A1 (en) 2005-12-01
US7576190B2 (en) 2009-08-18
ES2332100T3 (es) 2010-01-26

Similar Documents

Publication Publication Date Title
ATE444306T1 (de) Fgf-21-fusionsproteine
WO2005091944A3 (en) Glycol linked fgf-21 compounds
ATE517120T1 (de) Igf-1 fusion polypeptide und deren therapeutische verwendung
ATE406384T1 (de) Glp-1 fusion proteine
EP1845105A4 (de) Modifizierte exendine und anwendungen davon
DE60134251D1 (de) Verwendung von glp-2-peptiden
EP1617854A4 (de) Biologisch wirksame native biomatrix-zusammensetzung
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
PL374523A1 (pl) Koniugaty pochodna kalicheamycyny-nośnik
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
DK1881850T3 (da) GLP-1-PEGylerede forbindelser
BR0210383A (pt) compostos para o tratamento de distúrbios metabólicos
DE602007006492D1 (de) Derivatisierung des granulozytenkoloniestimulierenden faktors
ITRM20010464A1 (it) Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
DE60330757D1 (de) Verwendung von pyridylamiden als angiogenesehemmer
DE60331458D1 (de) Kombinationschemotherapie mit chlorotoxin
DE60238541D1 (de) Modifizierte transferrin-fusionsproteine
ATE307845T1 (de) N-alkylaziridinoprepolymere als dentalmasse
BRPI0414008B8 (pt) compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula
ATE452646T1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
ATE384423T1 (de) Heuwerbungsmaschine
DE602006018617D1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
ATE372990T1 (de) Oxazolderivat und deren verwendung als insulinsensibilisatoren
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
ITBO20050140A1 (it) Tessuto con principi attivi e metodo collegato di ricarica dei principi attivi